Stay updated on Pemigatinib Dose-Escalation Clinical Trial
Sign up to get notified when there's something new on the Pemigatinib Dose-Escalation Clinical Trial page.

Latest updates to the Pemigatinib Dose-Escalation Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedNo meaningful changes detected between the two screenshots of the Study Details page. The content and layout appear unchanged, including sections like Eligibility Criteria, Interventions, Primary and Secondary Outcomes, and Locations.SummaryDifference0.2%

- Check33 days agoChange Detected- Removed version v3.1.0 and added notice about government funding lapse and current NIH Clinical Center status with links, plus new version tag v3.2.0. Overall, the page now communicates current operating status and a newer version rather than the old one.SummaryDifference1%

- Check40 days agoChange DetectedUpdated disease naming from Plasma cell myeloma to Multiple myeloma and bumped the revision to v3.1.0.SummaryDifference0.1%

- Check54 days agoChange DetectedThe page now shows Revision: v3.0.2, replacing v3.0.1. The 'Back to Top' element was removed, indicating a minor navigational cleanup.SummaryDifference0.1%

- Check61 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1.SummaryDifference0.1%

- Check68 days agoChange DetectedThe web page has been updated to include new facility names and locations, as well as additional cancer-related resources and medications, while removing some previous resources and location details.SummaryDifference5%

Stay in the know with updates to Pemigatinib Dose-Escalation Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pemigatinib Dose-Escalation Clinical Trial page.